EIDX News and Press, Eidos Therapeutics Inc. From 08/07/20

SAN FRANCISCO, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Nasdaq: EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR), today announced that it has added two new...

Eidos Therapeutics (NASDAQ: EIDX ) : Q2 GAAP EPS of -$0.75 misses by $0.18 . More news on: Eidos Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SAN FRANCISCO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX),  today reported its financial results for the second quarter ended June 30, 2020 and provided an update on the company’s operations. “While the COVID-19 pandemic poses an u...

Eidos Therapeutics (NASDAQ: EIDX ): Q1 GAAP EPS of -$0.60 misses by $0.07 . Cash and cash equivalents totaled $196.5M Press Release More news on: Eidos Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,

SAN FRANCISCO, May 08, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX),  today reported its financial results for the first quarter ended March 31, 2020 and provided an update on the company’s operations. “We are living in unprecedented times as...

BridgeBio ( BBIO ) is something of a holding company with a number of public and private biopharma companies under its hood. It has a very long pipeline of some 20 candidates, 3 of them in late stage development. Phase 3 data readouts are next year. This is a good thing because right now, du...

Apellis Pharmaceuticals (NASDAQ: APLS ) initiated with Strong Buy rating and $86 (221% upside) price target at Raymond James. More news on: Apellis Pharmaceuticals, Inc., BioXcel Therapeutics, Inc., Eidos Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

An analyst at a large Canadian bank is adjusting his stance on biotechnology firm BridgeBio Pharma (NASDAQ: BBIO ) after the company upped its convertible senior notes offering. In a note sent out on Monday (March 9), George Farmer, managing director of biotechnology equity research at BMO C...

Eidos Therapeutics (NASDAQ: EIDX ): Q4 GAAP EPS of -$0.51 misses by $0.02 . More news on: Eidos Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SAN FRANCISCO, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the fourth quarter and full year ended December 31, 2019 and provided an update on the company’s recent achievements. “2019 marked ...